Compare Meta Platforms Inc (META) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs Twist Bioscience Corp — how do they compare? Meta Platforms Inc trades at $648.47 (market cap $1.64T), while Twist Bioscience Corp trades at $93.87 (market cap $5.45B). The key difference: Meta Platforms Inc is far larger — about 300.9× Twist Bioscience Corp's market cap, and Meta Platforms Inc pays a 0.33% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| META | TWST | |
|---|---|---|
Market Cap | $1.64T | $5.45B |
Volume | 24,093,972 | — |
Sector | Media | Health |
52-Week High | $790.00 | $102.88 |
52-Week Low | $525.72 | $24.16 |
Enterprise Value | $1.65T | $5.37B |
Dividend Yield | 0.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
META trades at $647.42, up 0.22% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong fundamentals with a P/E of 23.49, net income margin of 32.84%, and consistent earnings beats. Recent news highlights the launch of its Muse Spark AI model and a $21 billion deal with CoreWeave, though it faces a youth addiction lawsuit in Massachusetts.
Outlook remains positive with analyst consensus at Buy (79.37%) and a $817.32 price target, supported by robust revenue growth and AI investments. Key risks include regulatory lawsuits and high capital expenditures. The stock presents a growth opportunity but requires monitoring of legal and competitive pressures.
Twist Bioscience (TWST) trades at $87.41, down 6.86% today, with a bullish technical outlook despite recent earnings misses. The company shows strong revenue growth from $204M in 2022 to $377M in 2025, though it remains unprofitable with a -19.85% net margin. Analyst consensus is strongly bullish with 11 buy ratings and a $91.63 price target, while recent news highlights AI-driven drug discovery collaborations and upcoming Q3 earnings.
The stock presents growth potential through expanding synthetic biology applications and AI partnerships, but carries significant risk from persistent losses, negative cash flow, and high valuation multiples (P/S 13.94). Investors should weigh the company's innovation trajectory against its path to profitability amid competitive biotech pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
